Ascelia Pharma AB (publ) (ticker: ACE) today published its first quarter interim report for the period July 2019 – September 2019, which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/
SIGNIFICANT EVENTS IN THE PERIOD
- Detailed preparations for the start of the Phase III study for Mangoral (study name SPARKLE)
- The Phase III study will be conducted in Europe, the US and South Korea
SIGNIFICANT EVENTS AFTER THE PERIOD
- Dorthe Thrige, COO, will be leaving the company
FINANCIAL SUMMARY Q1 2019/2020 (JUL-SEP 2019)
- Operating result of SEK -13.9M (SEK -3.9M)
- Earnings per share of SEK -0.54 (SEK -0.26)
- Cash flow from operations of SEK -20.1M (SEK -3.8M)
- Cash and marketable securities of SEK 205.3M (SEK 51.2M)
“During this quarter, we continued to work diligently on our clinical portfolio with our drug candidates Mangoral and Oncoral in full focus. The most important near-term milestone for us is starting patient enrolment in the fully financed Phase III clinical study for Mangoral“, said Magnus Corfitzen, CEO at Ascelia Pharma.
A presentation for analysts, media and investors will be held on 8 November at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos and CMO Carl Bjartmar. The presentation will be held in English. The presentation can be followed live via the link:
It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website: https://www.ascelia.com/tag/reports-presentations/
To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 85 664 27 05
UK: +44 33 3300 9263
US: +1 833 526 8396
For more information, please contact:
Magnus Corfitzen, CEO
Tel. 46 735 179 110
Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60
The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on 8 November 2019.
About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.
Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.